TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
VCYT

Veracyte Inc

Healthcare · Diagnostics & Research

40.60$ +5.4% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Veracyte Inc (VCYT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 113.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 113.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 80Mio.

Largest Shareholders

Institutions

Institutions VCYT
Name Stake (%) Shares Change (%) Date
BlackRock Inc 16.39 13,172,618 +0.3 03/31/2026
FMR Inc 9.66 7,763,849 +35.3 03/31/2026
Artisan Partners Limited Partnership 6.89 5,538,404 +0.8 06/30/2026
State Street Corp 6.27 5,043,590 +15.7 03/31/2026
Vanguard Portfolio Management, LLC 5.53 4,444,730 +0.0 03/31/2026
Vanguard Capital Management, LLC 4.39 3,532,232 +0.0 03/31/2026
ARK Investment Management LLC 3.80 3,053,818 -21.4 03/31/2026
Dimensional Fund Advisors, Inc. 3.52 2,826,524 -1.9 06/30/2026

Funds

Funds VCYT
Name Stake (%) Shares Change (%) Date
iShares Core S&P Small-Cap ETF 6.05 4,866,333 +0.0 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 3.16 2,541,476 +0.3 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings VCYT
Person Role Shares Value As of Type
Stapley Marc Chief Executive Officer 432,073 17,542,164 $ Sep 2, 2026 direct
Chambers Rebecca Chief Financial Officer 166,025 6,740,615 $ Sep 4, 2026 direct
Febbo Phillip G. Chief Scientific & Med Officer 133,048 5,401,749 $ Sep 4, 2026 direct
McGuire Annie EVP, General Counsel 131,160 5,325,096 $ Sep 4, 2026 direct
Leite John Global Chief Commercial Off 128,344 5,210,766 $ Sep 2, 2026 direct
Wygant Jonathan VP, Chief Accounting Officer 43,226 1,754,976 $ Sep 2, 2026 direct
Bhanji Muna Director 42,718 1,734,351 $ Sep 1, 2026 direct
Holstein Jens Director 27,471 1,115,323 $ Sep 14, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 14, 2026 Holstein Jens Director Sell 5,000 40.95 204,747
Sep 4, 2026 McGuire Annie EVP, General Counsel Sell 1,100 43.67 48,039
Sep 4, 2026 McGuire Annie EVP, General Counsel Sell 2,154 42.79 92,173
Sep 4, 2026 Chambers Rebecca Chief Financial Officer Sell 1,175 43.71 51,364
Sep 4, 2026 Chambers Rebecca Chief Financial Officer Sell 2,477 42.81 106,030
Sep 4, 2026 Febbo Phillip G. Chief Scientific & Med Officer Sell 2,705 43.66 118,105
Sep 4, 2026 Febbo Phillip G. Chief Scientific & Med Officer Sell 10,405 42.89 446,305
Sep 2, 2026 Leite John Global Chief Commercial Off Other 3,961 44.88 177,770
Sep 2, 2026 McGuire Annie EVP, General Counsel Other 3,215 44.88 144,289
Sep 2, 2026 Chambers Rebecca Chief Financial Officer Other 3,603 44.88 161,703
Sep 2, 2026 Febbo Phillip G. Chief Scientific & Med Officer Other 3,639 44.88 163,318
Sep 2, 2026 Wygant Jonathan VP, Chief Accounting Officer Other 1,361 44.88 61,082
Sep 2, 2026 Stapley Marc Chief Executive Officer Other 8,782 44.88 394,136
Sep 1, 2026 Bhanji Muna Director Sell 1,864 42.97 80,096

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?